MLLStart! advised Clinical Research Ventures in its investment into BioVersys
MLLStart! advised Clinical Research Ventures (CR Ventures), a Singapore, Frankfurt and Boston based global life-science investor with a focus on companies entering Phase I or II clinical trials in its investment into BioVersys, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics. The investment forms part of the recently closed series B round and will allow BioVersys to advance its two lead assets for multi-drug resistant bacterial infections through initial clinical trials. In November BioVersys announced it had successfully dosed the first patients in its phase I trial with BV100.
